Vertex Pharma (VRTX) Receives EC Approval of KALYDECO in Certain Patients with CF
Vertex Pharma (Nasdaq: VRTX) announced that the European Commission has approved KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)